Axonics rises on FDA nod for incontinence treatment device

Axonics

31/01/2023 15:20

** Shares of medical device maker Axonics Inc  AXNX.O  rise
1.8% to $62.17
    ** Co says FDA has approved its rechargeable device to
improve bladder function in patients suffering from overactive
bladder causing incontinence 
    ** The device, Axonics R20, belongs to a class of devices
called sacral neuromodulation system
    ** Sacral neuromodulation is a minimally invasive therapy to
treat urinary incontinence, urinary retention and fecal
incontinence caused by treatment-resistant overactive bladder   
    ** Axonics R20 is labeled for a functional life of at least
20 years and needs to be recharged only once every 6 to 10
months - AXNX
    ** Co plans to commercially launch the product in the U.S.
in March
    ** Including session's move, stock has risen ~30.2% in the
past 12 months
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))